Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models.

Friese-Hamim M, Bladt F, Locatelli G, Stammberger U, Blaukat A.

Am J Cancer Res. 2017 Apr 1;7(4):962-972. eCollection 2017.

2.

Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.

Francica P, Nisa L, Aebersold DM, Langer R, Bladt F, Blaukat A, Stroka D, Martínez MR, Zimmer Y, Medová M.

Clin Cancer Res. 2016 Nov 1;22(21):5322-5336. Epub 2016 May 16.

3.

Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.

Mikami K, Medová M, Nisa L, Francica P, Glück AA, Tschan MP, Blaukat A, Bladt F, Aebersold DM, Zimmer Y.

Mol Cancer Res. 2015 Dec;13(12):1544-53. doi: 10.1158/1541-7786.MCR-15-0022. Epub 2015 Sep 10.

4.

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.

Leiser D, Medová M, Mikami K, Nisa L, Stroka D, Blaukat A, Bladt F, Aebersold DM, Zimmer Y.

Mol Oncol. 2015 Aug;9(7):1434-46. doi: 10.1016/j.molonc.2015.04.001. Epub 2015 Apr 14.

5.

Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.

Dorsch D, Schadt O, Stieber F, Meyring M, Grädler U, Bladt F, Friese-Hamim M, Knühl C, Pehl U, Blaukat A.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1597-602. doi: 10.1016/j.bmcl.2015.02.002. Epub 2015 Feb 16.

PMID:
25736998
6.

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models.

Bladt F, Friese-Hamim M, Ihling C, Wilm C, Blaukat A.

Cancers (Basel). 2014 Aug 19;6(3):1736-52. doi: 10.3390/cancers6031736.

7.

The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.

Medová M, Pochon B, Streit B, Blank-Liss W, Francica P, Stroka D, Keogh A, Aebersold DM, Blaukat A, Bladt F, Zimmer Y.

Mol Cancer Ther. 2013 Nov;12(11):2415-24. doi: 10.1158/1535-7163.MCT-13-0151. Epub 2013 Sep 23.

8.

EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.

Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Grädler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O, Blaukat A.

Clin Cancer Res. 2013 Jun 1;19(11):2941-51. doi: 10.1158/1078-0432.CCR-12-3247. Epub 2013 Apr 3.

9.

Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells.

Humbert M, Medová M, Aebersold DM, Blaukat A, Bladt F, Fey MF, Zimmer Y, Tschan MP.

Biochem Biophys Res Commun. 2013 Feb 8;431(2):264-9. doi: 10.1016/j.bbrc.2012.12.120. Epub 2013 Jan 9.

PMID:
23313490
10.

Fine tuning of the threshold of T cell selection by the Nck adapters.

Roy E, Togbe D, Holdorf A, Trubetskoy D, Nabti S, Küblbeck G, Schmitt S, Kopp-Schneider A, Leithäuser F, Möller P, Bladt F, Hämmerling GJ, Arnold B, Pawson T, Tafuri A.

J Immunol. 2010 Dec 15;185(12):7518-26. doi: 10.4049/jimmunol.1000008. Epub 2010 Nov 15.

11.

Nck adaptors are positive regulators of the size and sensitivity of the T-cell repertoire.

Roy E, Togbe D, Holdorf AD, Trubetskoy D, Nabti S, Küblbeck G, Klevenz A, Kopp-Schneider A, Leithäuser F, Möller P, Bladt F, Hämmerling G, Arnold B, Pawson T, Tafuri A.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15529-34. doi: 10.1073/pnas.1009743107. Epub 2010 Aug 13.

12.

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.

Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O.

Clin Cancer Res. 2009 Sep 1;15(17):5445-56. doi: 10.1158/1078-0432.CCR-08-2980. Epub 2009 Aug 25.

13.

Nck adaptor proteins control the organization of neuronal circuits important for walking.

Fawcett JP, Georgiou J, Ruston J, Bladt F, Sherman A, Warner N, Saab BJ, Scott R, Roder JC, Pawson T.

Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20973-8. Epub 2007 Dec 18.

14.

Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes.

Jones N, Blasutig IM, Eremina V, Ruston JM, Bladt F, Li H, Huang H, Larose L, Li SS, Takano T, Quaggin SE, Pawson T.

Nature. 2006 Apr 6;440(7085):818-23. Epub 2006 Mar 8.

PMID:
16525419
15.

c-Abl phosphorylates Dok1 to promote filopodia during cell spreading.

Woodring PJ, Meisenhelder J, Johnson SA, Zhou GL, Field J, Shah K, Bladt F, Pawson T, Niki M, Pandolfi PP, Wang JY, Hunter T.

J Cell Biol. 2004 May 24;165(4):493-503. Epub 2004 May 17.

16.

Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses.

Mak TW, Shahinian A, Yoshinaga SK, Wakeham A, Boucher LM, Pintilie M, Duncan G, Gajewska BU, Gronski M, Eriksson U, Odermatt B, Ho A, Bouchard D, Whorisky JS, Jordana M, Ohashi PS, Pawson T, Bladt F, Tafuri A.

Nat Immunol. 2003 Aug;4(8):765-72. Epub 2003 Jun 29.

PMID:
12833154
17.

The murine Nck SH2/SH3 adaptors are important for the development of mesoderm-derived embryonic structures and for regulating the cellular actin network.

Bladt F, Aippersbach E, Gelkop S, Strasser GA, Nash P, Tafuri A, Gertler FB, Pawson T.

Mol Cell Biol. 2003 Jul;23(13):4586-97.

18.

Epidermolysis bullosa and embryonic lethality in mice lacking the multi-PDZ domain protein GRIP1.

Bladt F, Tafuri A, Gelkop S, Langille L, Pawson T.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6816-21. Epub 2002 Apr 30.

19.

Enteropathogenic E. coli Tir binds Nck to initiate actin pedestal formation in host cells.

Gruenheid S, DeVinney R, Bladt F, Goosney D, Gelkop S, Gish GD, Pawson T, Finlay BB.

Nat Cell Biol. 2001 Sep;3(9):856-9.

PMID:
11533668
20.

ICOS is essential for effective T-helper-cell responses.

Tafuri A, Shahinian A, Bladt F, Yoshinaga SK, Jordana M, Wakeham A, Boucher LM, Bouchard D, Chan VS, Duncan G, Odermatt B, Ho A, Itie A, Horan T, Whoriskey JS, Pawson T, Penninger JM, Ohashi PS, Mak TW.

Nature. 2001 Jan 4;409(6816):105-9.

PMID:
11343123
21.

The branchial arches and HGF are growth-promoting and chemoattractant for cranial motor axons.

Caton A, Hacker A, Naeem A, Livet J, Maina F, Bladt F, Klein R, Birchmeier C, Guthrie S.

Development. 2000 Apr;127(8):1751-66.

22.

The role of SF/HGF and c-Met in the development of skeletal muscle.

Dietrich S, Abou-Rebyeh F, Brohmann H, Bladt F, Sonnenberg-Riethmacher E, Yamaai T, Lumsden A, Brand-Saberi B, Birchmeier C.

Development. 1999 Apr;126(8):1621-9.

23.

Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo.

Hartmann G, Prospero T, Brinkmann V, Ozcelik C, Winter G, Hepple J, Batley S, Bladt F, Sachs M, Birchmeier C, Birchmeier W, Gherardi E.

Curr Biol. 1998 Jan 29;8(3):125-34. Erratum in: Curr Biol 1998 Oct 8;8(20):R739. Ozcelik O [corrected to Ozcelik C].

24.

The functions of HGF/SF and its receptor, the c-Met tyrosine kinase, in mammalian development.

Birchmeier C, Bladt F, Yamaai T.

Ciba Found Symp. 1997;212:169-77; discussion 177-82.

PMID:
9524770
25.

Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons.

Ebens A, Brose K, Leonardo ED, Hanson MG Jr, Bladt F, Birchmeier C, Barres BA, Tessier-Lavigne M.

Neuron. 1996 Dec;17(6):1157-72.

26.

Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud.

Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C.

Nature. 1995 Aug 31;376(6543):768-71.

PMID:
7651534
27.

Scatter factor/hepatocyte growth factor is essential for liver development.

Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, Birchmeier C.

Nature. 1995 Feb 23;373(6516):699-702.

PMID:
7854452
28.
29.

Transient and locally restricted expression of the ros1 protooncogene during mouse development.

Sonnenberg E, Gödecke A, Walter B, Bladt F, Birchmeier C.

EMBO J. 1991 Dec;10(12):3693-702.

Supplemental Content

Support Center